1-(4-(4-(5-chloro-2-methoxyphenyl)pyrimidin-2-ylamino)piperidin-1-yl)-2,2-dimethylpropan-1-one | 1260151-06-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-(4-(4-(5-chloro-2-methoxyphenyl)pyrimidin-2-ylamino)piperidin-1-yl)-2,2-dimethylpropan-1-one
• 英文别名: 1-[4-[[4-(5-Chloro-2-methoxyphenyl)pyrimidin-2-yl]amino]piperidin-1-yl]-2,2-dimethylpropan-1-one
• CAS: 1260151-06-1
• 化学式: C₂₁H₂₇ClN₄O₂
• 分子量: 402.924
• InChiKey: FBTQYHPKFBVWJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  67.4
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] PYRIMINE COMPOUNDS AND METHODS OF MAKING AND USING SAME<br/>[FR] COMPOSÉS DE PYRAMINE AINSI QUE LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC

  公开号：WO2010151747A1

  公开（公告）日：2010-12-29

  Disclosed herein are pyrimidinyl compounds that are contemplated to be modulators of cystic fibrosis transmembrane regulators (CFTR), and methods of making and using same. Also provided are pharmaceutical compositions and methods of treating disorders associated with cystic fibrosis transmembrane regulators, such as airway inflammation, cystic fibrosis, and the like.

  本文披露了一种嘧啶基化合物，被认为是囊性纤维化跨膜调节蛋白（CFTR）的调节剂，并提供了制备和使用这些化合物的方法。还提供了与囊性纤维化跨膜调节蛋白相关的疾病的药物组合物和治疗方法，如气道炎症、囊性纤维化等。
• [EN] ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS<br/>[FR] COMPOSÉS ARYLPYRIMIDINES ET THÉRAPIE DE COMBINAISON COMPRENANT CEUX-CI POUR TRAITER UNE MUCOVISCIDOSE ET DES TROUBLES APPARENTÉS
  申请人：CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC

  公开号：WO2011008931A2

  公开（公告）日：2011-01-20

  Provided herein are pharmaceutical compositions comprising an arylpyrimidine compound that modulates the activity of cystic fibrosis transmembrane regulator (CFTR) protein and a second compound that modulates the activity of a CFTR protein. Also provided are methods of treating a disorder associated with CFTR protein function by administering an arylpyrimidine compound that modulates the activity of a CFTR protein and a second compound that modulates the activity of a CFTR protein. The combination therapy can be used to treat, for example, airway inflammation and cystic fibrosis.